ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2239

Efficacy of Ketoprofen Lysine Salt in Reducing Inflammation and Pain in Primary Osteoarthritis of the Hand: Preliminary Results of a Retrospective and Prospective Clinical Trial

Maurizio Muratore1, Laura Quarta1, Antonella Grimaldi1, Daniela Costanza1, Luigi Lanata2, Michela Bagnasco2, Alessandra Monguzzi2 and Eugenio Quarta1, 1Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy, 2Medical Department, Dompé SpA, Milan, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Doppler ultrasound, Hand disorders, Inflammation, osteoarthritis and pain management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Osteoarthritis - Clinical Aspects: Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Osteoarthritis (OA) is a common progressive joint disease and a leading cause of musculoskeletal pain and functional disability worldwide. Despite various interventional treatment approaches such as non-steroidal antinflammatory drugs (NSAIDs), pain management of OA remains suboptimal. Among NSAIDs, ketoprofen lysine salt (KSL) has a marked analgesic effect, through both its anti-inflammatory action and a central action. The primary aim of our study was to evaluate the efficacy of KSL in reducing the severity of osteoarticular pain. Secondary aims were grip strength assessment, duration and severity of swelling, acute exacerbations frequency and inflammation grade.

Methods: This was a retrospective and prospective clinical trial, including 58 post-menopausal women (>50 years) affected by primary osteoarthritis of the hand. All patients (pz) reported pain and swelling at least in 3 interphalangeal joints (IF) of the hands. Pz were randomized into 2 groups: Group A (30 pz, 105 IF) took KSL (160 mg/die) for 10 days plus glucosamine (500 mg) and chondroitin sulphate (400 mg) for 20 days. Group B (28 pz, 95 IF) received only glucosamine (500 mg) and chondroitin sulphate (400 mg) for 20 days. Pulsed wave (PW) Doppler (Esaote Mylab 25 Gold equipped with a 12-18 MHz multi-frequency transducer) was performed on the dorsal and palmar side of IF, with longitudinal and transverse scans, assessing synovitis/effusion and PW-Doppler signal (OMERACT scale: 0-3). Clinical assessments of pz were performed at day 1 (T0) and after 5,10,15,20 days (T1,T2,T3,T4). At each visit Visual Analog Scale for Pain (VAS Pain) and grip strength were recorded.

Results : Pain improved in 24 Group A pz (mean VAS score decreased from 70 to 16) and 70/105 IF showed an improvement in PW Doppler. None of these pz reported exacerbations. Also grip strength improved by an average of 50%. On the contrary, only 10/28 Group B pz obtained an improvement of pain (mean VAS score decreased from 70 to 55). PW Doppler improved in 20/95 IF, ≥1 exacerbations were reported by 12 pz and grip strength remained unchanged.

Conclusion : These results demonstrate that the addition of KSL is highly effective in reducing joint inflammation and pain in women with primary osteoarthritis of the hand. The reduction in the number of exacerbations in the group of patients treated with KSL also suggests that the use of this NSAID may reduce relapses lessening the bone and cartilage damage and joint deformities.


Disclosure:

M. Muratore,
None;

L. Quarta,
None;

A. Grimaldi,
None;

D. Costanza,
None;

L. Lanata,

Dompè SpA,

3;

M. Bagnasco,

Dompè SpA,

3;

A. Monguzzi,

Dompè SpA,

3;

E. Quarta,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-ketoprofen-lysine-salt-in-reducing-inflammation-and-pain-in-primary-osteoarthritis-of-the-hand-preliminary-results-of-a-retrospective-and-prospective-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology